CN107922332A - 阿普斯特的新形式及其制备方法 - Google Patents

阿普斯特的新形式及其制备方法 Download PDF

Info

Publication number
CN107922332A
CN107922332A CN201680050410.4A CN201680050410A CN107922332A CN 107922332 A CN107922332 A CN 107922332A CN 201680050410 A CN201680050410 A CN 201680050410A CN 107922332 A CN107922332 A CN 107922332A
Authority
CN
China
Prior art keywords
apremilast
suspension
obtains
temperature
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680050410.4A
Other languages
English (en)
Chinese (zh)
Inventor
方晓萍
罗伟硕
王冠勋
林育生
胡聪成
黄原章
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scinopharm Taiwan Ltd
Original Assignee
Scinopharm Taiwan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scinopharm Taiwan Ltd filed Critical Scinopharm Taiwan Ltd
Publication of CN107922332A publication Critical patent/CN107922332A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
CN201680050410.4A 2015-08-28 2016-08-25 阿普斯特的新形式及其制备方法 Pending CN107922332A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562211280P 2015-08-28 2015-08-28
US62/211,280 2015-08-28
US201662279147P 2016-01-15 2016-01-15
US62/279,147 2016-01-15
PCT/SG2016/050413 WO2017039537A1 (en) 2015-08-28 2016-08-25 Novel forms of apremilast and the process of making the same

Publications (1)

Publication Number Publication Date
CN107922332A true CN107922332A (zh) 2018-04-17

Family

ID=58097541

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680050410.4A Pending CN107922332A (zh) 2015-08-28 2016-08-25 阿普斯特的新形式及其制备方法

Country Status (9)

Country Link
US (1) US9765026B2 (enExample)
EP (1) EP3341360A4 (enExample)
JP (1) JP2018528948A (enExample)
KR (1) KR20180036791A (enExample)
CN (1) CN107922332A (enExample)
CA (1) CA2994217A1 (enExample)
IL (1) IL257195A (enExample)
TW (1) TWI613191B (enExample)
WO (1) WO2017039537A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106977444A (zh) * 2016-01-18 2017-07-25 重庆医药工业研究院有限责任公司 一种阿普斯特无定型的制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016174685A1 (en) * 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
US10544097B2 (en) * 2015-08-27 2020-01-28 Msn Laboratories Private Limited Solid state forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide and process for preparation thereof
EA038882B1 (ru) * 2016-03-30 2021-11-02 Сарудбхава Формулатионс Приват Лимитед Фармацевтическая композиция апремиласта
CN107686461A (zh) * 2016-08-04 2018-02-13 广东东阳光药业有限公司 阿普斯特的溶剂化物及其制备方法和用途
WO2019021303A1 (en) * 2017-07-23 2019-01-31 Alkem Laboratories Limited NOVEL PROCESS FOR THE PREPARATION OF APREMILAST IN AMORPHOUS FORM
CN108440381A (zh) * 2018-03-15 2018-08-24 威海迪素制药有限公司 一种阿普斯特新晶型h及其制备方法
CA3216107A1 (en) * 2021-04-26 2022-11-03 Amgen Inc. Process for synthesizing apremilast
WO2023120466A1 (ja) * 2021-12-23 2023-06-29 沢井製薬株式会社 アプレミラスト水和物含有製剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316836A (zh) * 2005-11-01 2008-12-03 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的二氢异吲哚酮类
CN101885731A (zh) * 2009-05-14 2010-11-17 天津和美生物技术有限公司 噻吩衍生物
CN102046167A (zh) * 2008-03-27 2011-05-04 细胞基因公司 包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、其组合物及其用途
WO2014068388A1 (en) * 2012-10-29 2014-05-08 Glaxo Group Limited 2 substituted cephem compounds
CN103906733A (zh) * 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
CN107922326A (zh) * 2015-06-09 2018-04-17 雷迪博士实验室有限公司 阿普斯特的制备方法及其中间体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US8981117B2 (en) 2012-09-14 2015-03-17 Celgene Corporation Processes for the preparation of isoindole compounds and isotopologues thereof
EP2730278A1 (en) 2012-11-08 2014-05-14 Ratiopharm GmbH Composition melt
IN2014MU01283A (enExample) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
CN104447445B (zh) 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
WO2016189486A1 (en) 2015-05-26 2016-12-01 Lupin Limited An improved process for preparation of apremilast and novel polymorphs thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316836A (zh) * 2005-11-01 2008-12-03 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的二氢异吲哚酮类
CN102046167A (zh) * 2008-03-27 2011-05-04 细胞基因公司 包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、其组合物及其用途
CN101885731A (zh) * 2009-05-14 2010-11-17 天津和美生物技术有限公司 噻吩衍生物
CN103906733A (zh) * 2011-06-24 2014-07-02 安姆根有限公司 Trpm8拮抗剂及其在治疗中的用途
WO2014068388A1 (en) * 2012-10-29 2014-05-08 Glaxo Group Limited 2 substituted cephem compounds
CN107922326A (zh) * 2015-06-09 2018-04-17 雷迪博士实验室有限公司 阿普斯特的制备方法及其中间体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106977444A (zh) * 2016-01-18 2017-07-25 重庆医药工业研究院有限责任公司 一种阿普斯特无定型的制备方法
CN106977444B (zh) * 2016-01-18 2021-10-08 重庆医药工业研究院有限责任公司 一种阿普斯特无定型的制备方法

Also Published As

Publication number Publication date
WO2017039537A1 (en) 2017-03-09
KR20180036791A (ko) 2018-04-09
US20170057916A1 (en) 2017-03-02
JP2018528948A (ja) 2018-10-04
IL257195A (en) 2018-03-29
TWI613191B (zh) 2018-02-01
US9765026B2 (en) 2017-09-19
EP3341360A1 (en) 2018-07-04
EP3341360A4 (en) 2019-01-23
CA2994217A1 (en) 2017-03-09
TW201718485A (zh) 2017-06-01

Similar Documents

Publication Publication Date Title
CN107922332A (zh) 阿普斯特的新形式及其制备方法
JP7345581B2 (ja) Ｐｄｅ４抑制活性を有する化合物の製造方法
JP4638491B2 (ja) シナカルセト塩酸塩結晶フォームｉの調製方法
JP2020512380A (ja) ６−（シクロプロパンカルボキサミド）−４−（（２−メトキシ−３−（１−メチル−１Ｈ−１，２，４−トリアゾール−３−イル）フェニル）アミノ）−Ｎ−（メチル−ｄ３）ピリダジン−３−カルボキサミドの結晶形態
TW201731812A (zh) 用於製備喹啉衍生物之方法
JP2008507566A6 (ja) シナカルセト塩酸塩結晶フォームｉの調製方法
TW201617319A (zh) （２ｓ，３ｓ）７－氟－２－（４－氟苯基）－３－（１－甲基－１ｈ－１，２，４－三唑－５－基）－４－側氧基－１，２，３，４－四氫喹啉－５－羧酸甲酯之共形成體鹽及其製備方法
JP6691218B2 (ja) 選択的なｓ１ｐ１受容体アゴニストの新規な結晶形及びその製造方法
KR20180040694A (ko) 이브루티닙의 결정형 및 그 제조 방법
EP2883870B1 (en) Method for producing 1,4-benzoxazine compound
CN101774969B (zh) 硫酸伊伐布雷定及其i型结晶的制备方法
WO2015014984A1 (en) A process for preparing rifaximin k
US20050277650A1 (en) Process for preparing aripirazole hydrate
KR100990046B1 (ko) 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
WO2017131218A1 (ja) アジルサルタン及びその製造方法
WO2009090663A1 (en) Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
CN111732586B (zh) 含炔基化合物盐的晶型、制备方法及应用
CN106146485B (zh) 一种制备泰地唑胺的方法及其得到的泰地唑胺结晶体
JP2012506367A (ja) 結晶性モンテルカストの塩
KR20090044694A (ko) 모사프리드의 신규한 동질이상체 및 유사동질이상체
CN111995571A (zh) 一种瑞戈非尼与马来酸的共晶及其制备方法
CN105859611A (zh) 一种阿扎那韦硫酸氢盐a型结晶的制备方法
CN116102399B (zh) 一种联苯苄唑中间体4-(α-氯代苄基)联苯的制备方法
JP7426832B2 (ja) 新規結晶構造を有するイグラチモド及びその製造方法
JP5613780B2 (ja) ラミブジンシュウ酸塩及びその製造方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180417